FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1976261196> ?p ?o ?g. }

• W1976261196 endingPage "416" @default.
• W1976261196 startingPage "412" @default.
• W1976261196 abstract "Vorinostat, an orally active histone deacetylase inhibitor, was approved in October 2006 by the US Food and Drug Administration for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease during or after treatment with 2 systemic therapies.A multicenter, open-label phase IIb trial evaluated the activity and safety of vorinostat 400 mg orally daily in patients with > or = stage IB, persistent, progressive, or treatment-refractory mycosis fungoides or Sézary syndrome CTCL subtypes. We report the safety and tolerability of long-term vorinostat therapy in patients who experienced clinical benefit in the previous phase IIb study.As of December 11, 2008, 6 of 74 patients enrolled in the original study had received vorinostat for > or = 2 years: median age, 65 years; median number of previous therapies, 2.5; median time from diagnosis to enrollment, 1.8 years. At enrollment into the continuation phase, 5 of the 6 patients had achieved an objective response, and 1 patient had prolonged stable disease. During the follow-up study, the most common drug-related grade 1-4 adverse events (AEs) were diarrhea, nausea, fatigue, and alopecia (6, 5, 4, and 3 patients, respectively). Incidence of grade 3/4 AEs was low: anorexia (n = 1), increased creatinine phosphokinase (n = 1), pulmonary embolism (n = 1), rash (n = 1), and thrombocytopenia (n = 1). Five patients have discontinued the study drug, and 1 patient is continuing therapy.This post hoc subset analysis provides evidence for the long-term safety and clinical benefit of vorinostat in heavily pretreated patients with CTCL, regardless of previous treatment failures." @default.
• W1976261196 created "2016-06-24" @default.
• W1976261196 creator A5001315602 @default.
• W1976261196 creator A5005902360 @default.
• W1976261196 creator A5006764092 @default.
• W1976261196 creator A5007499336 @default.
• W1976261196 creator A5013186479 @default.
• W1976261196 creator A5031357885 @default.
• W1976261196 creator A5035210370 @default.
• W1976261196 creator A5037047474 @default.
• W1976261196 creator A5041491201 @default.
• W1976261196 creator A5046824106 @default.
• W1976261196 creator A5064673685 @default.
• W1976261196 creator A5067331026 @default.
• W1976261196 creator A5068807193 @default.
• W1976261196 creator A5076537819 @default.
• W1976261196 date "2009-12-01" @default.
• W1976261196 modified "2023-09-25" @default.
• W1976261196 title "Evaluation of the Long-Term Tolerability and Clinical Benefit of Vorinostat in Patients With Advanced Cutaneous T-Cell Lymphoma" @default.
• W1976261196 cites W1739537573 @default.
• W1976261196 cites W1976298557 @default.
• W1976261196 cites W1980469090 @default.
• W1976261196 cites W2000150347 @default.
• W1976261196 cites W2005429148 @default.
• W1976261196 cites W2009204250 @default.
• W1976261196 cites W2022285476 @default.
• W1976261196 cites W2029517507 @default.
• W1976261196 cites W2030145184 @default.
• W1976261196 cites W2030822086 @default.
• W1976261196 cites W2037975991 @default.
• W1976261196 cites W2053344100 @default.
• W1976261196 cites W2058232002 @default.
• W1976261196 cites W2070433411 @default.
• W1976261196 cites W2071115015 @default.
• W1976261196 cites W2072936571 @default.
• W1976261196 cites W2079029980 @default.
• W1976261196 cites W2096160655 @default.
• W1976261196 cites W2103789449 @default.
• W1976261196 cites W2107040737 @default.
• W1976261196 cites W2110957729 @default.
• W1976261196 cites W2118335184 @default.
• W1976261196 cites W2135619784 @default.
• W1976261196 cites W2140608535 @default.
• W1976261196 cites W2141127880 @default.
• W1976261196 cites W2161055005 @default.
• W1976261196 cites W2169409181 @default.
• W1976261196 cites W91395500 @default.
• W1976261196 cites W2100103468 @default.
• W1976261196 doi "https://doi.org/10.3816/clm.2009.n.082" @default.
• W1976261196 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19951879" @default.
• W1976261196 hasPublicationYear "2009" @default.
• W1976261196 type Work @default.
• W1976261196 sameAs 1976261196 @default.
• W1976261196 citedByCount "89" @default.
• W1976261196 countsByYear W19762611962012 @default.
• W1976261196 countsByYear W19762611962013 @default.
• W1976261196 countsByYear W19762611962014 @default.
• W1976261196 countsByYear W19762611962015 @default.
• W1976261196 countsByYear W19762611962016 @default.
• W1976261196 countsByYear W19762611962017 @default.
• W1976261196 countsByYear W19762611962018 @default.
• W1976261196 countsByYear W19762611962019 @default.
• W1976261196 countsByYear W19762611962020 @default.
• W1976261196 countsByYear W19762611962021 @default.
• W1976261196 countsByYear W19762611962022 @default.
• W1976261196 countsByYear W19762611962023 @default.
• W1976261196 crossrefType "journal-article" @default.
• W1976261196 hasAuthorship W1976261196A5001315602 @default.
• W1976261196 hasAuthorship W1976261196A5005902360 @default.
• W1976261196 hasAuthorship W1976261196A5006764092 @default.
• W1976261196 hasAuthorship W1976261196A5007499336 @default.
• W1976261196 hasAuthorship W1976261196A5013186479 @default.
• W1976261196 hasAuthorship W1976261196A5031357885 @default.
• W1976261196 hasAuthorship W1976261196A5035210370 @default.
• W1976261196 hasAuthorship W1976261196A5037047474 @default.
• W1976261196 hasAuthorship W1976261196A5041491201 @default.
• W1976261196 hasAuthorship W1976261196A5046824106 @default.
• W1976261196 hasAuthorship W1976261196A5064673685 @default.
• W1976261196 hasAuthorship W1976261196A5067331026 @default.
• W1976261196 hasAuthorship W1976261196A5068807193 @default.
• W1976261196 hasAuthorship W1976261196A5076537819 @default.
• W1976261196 hasConcept C104317684 @default.
• W1976261196 hasConcept C126322002 @default.
• W1976261196 hasConcept C141071460 @default.
• W1976261196 hasConcept C185592680 @default.
• W1976261196 hasConcept C197934379 @default.
• W1976261196 hasConcept C2776262904 @default.
• W1976261196 hasConcept C2778305200 @default.
• W1976261196 hasConcept C2778375690 @default.
• W1976261196 hasConcept C2778570526 @default.
• W1976261196 hasConcept C2780580376 @default.
• W1976261196 hasConcept C55493867 @default.
• W1976261196 hasConcept C64927066 @default.
• W1976261196 hasConcept C71924100 @default.
• W1976261196 hasConcept C90924648 @default.
• W1976261196 hasConceptScore W1976261196C104317684 @default.
• W1976261196 hasConceptScore W1976261196C126322002 @default.
• W1976261196 hasConceptScore W1976261196C141071460 @default.

• next